Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol.
L E Hollister, H Gillespie
Clinical Pharmacology & Therapeutics July 1975 DOI: 10.1002/cpt197518180 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Human volunteers |
| Interventions | delta-9-tetrahydrocannabinol (THC) cannabinol (CBN) cannabidiol (CBD) |
| Dose | 20 mg THC; 40 mg CBN; 40 mg CBD |
| Topics | Cannabis CBD |
| Key findings | CBN at 40 mg did not detectably alter the quality, intensity, or duration of THC's effects, while CBD at 40 mg tended to delay THC's onset, prolong its effects, and make them somewhat more intense. The authors judge this interaction slight and argue it provides no reason to abandon dosing marijuana for clinical studies solely on THC content. |
Abstract
Oral doses of delta-9-tetrahydrocannabinol (THC) 20 mg, combined with placebo or with 40 mg dses of cannabinol (CBN) and cannabidiol (CBD), were given to volunteers. The combination of THC with CBN produced no detectable changes in the quality, intensity, or duration of the effects of THC alone. The THC-CBD combination tended to delay onset and prolong effects of THC, while making them somewhat more intense. Even this interactive effect was slight, providing no reason to abandon the current practice of basing doses of marihuana for clinical studies solely on THC content.
Comparable studies
Other experimental studies on CBD, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity Healthy volunteers experienced with cannabis but not regular users | 2019 | Within-subjects experimental design | n = 17 |
| Pharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT2A receptor. HEK 293 cells and rat primary cortical neurons | 2025 | Laboratory study | |
| Placebo Effects of Edible Cannabis: Reported Intoxication Effects at a 30-Minute Delay Participants | 2017 | Within-subjects experimental design | n = 20 |
| THC, CBD and minor cannabinoid CBDV differently modulate hippocampal neurons firing. Cultured hippocampal neurons | 2025 | Experimental study | |
| Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study Participants with anxiety symptoms who were not using cannabis or who used cannabis... | 2024 | Nonequivalent control group quasiexperimental design | n = 300 |
Citations in the library
Cited by 14
- Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug Brazilian Journal of Medical and Biological Research April 1, 2006
- Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition Psychopharmacology May 1, 2019
- Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids Behavioural Pharmacology September 1, 2005
- THC and CBD: Similarities and differences between siblings. Neuron February 1, 2023
- How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neuroscience & Biobehavioral Reviews September 30, 2019
and 9 more in the library